RBC Capital Reiterates Outperform on Axsome Therapeutics, Maintains $131 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $131.
July 22, 2024 | 1:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Axsome Therapeutics and maintained a price target of $131.
The reiteration of an Outperform rating and a maintained price target of $131 by a reputable analyst from RBC Capital is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100